Can Ocugen Stock Keep Churning Higher? [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
performance of small-cap growth stocks this year. (See the following graph.) What's fueling this rally? Is Ocugen's stock still a strong buy? Let's dig deeper to find answers to these questions. A promising eye gene therapy At the heart of Ocugen's ascent lies OCU400, an experimental gene therapy headed into late-stage testing for retinitis pigmentosa (RP), a cluster of rare, degenerative eye conditions that erode vision by gradually dismantling the retina's cells. This genetic affliction, affecting approximately 2 million individuals globally, is projected to reach a therapeutic market value of $21 billion by 2033. Given their significant price points, the buzz surrounding ocular gene therapies is not without merit. For perspective, Roche 's Luxturna, a similar treatment acquired for a hefty $4.8 billion, commands an $850,000 price tag for treating both eyes. While not an exact parallel, Luxturna sheds light on the potential pricing strategy for OCU400, should it gain appro
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGNGlobeNewswire
- INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenGlobeNewswire
- Ocugen, Inc. (NASDAQ: OCGN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.MarketBeat
- INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the FirmAccesswire
OCGN
Earnings
- 5/14/24 - Beat
OCGN
Sec Filings
- 5/14/24 - Form 8-K
- 5/14/24 - Form 10-Q
- 5/10/24 - Form 8-A12G
- OCGN's page on the SEC website